Abald, B., Bjorkman, J. A., Edstrom, T. et al. The role of central nervous system beta-adrenoreceptors in the prevention of ventricular fibrilla¬tion through augmentation of cardiac vagal tone (abstract). J. Am. Coll. Cardiol., 17:165A, 1991.
Bakris, G. L., Fonseca, V., Katholi, R. E. et al. Metabolic effects of carvedilol versus metoprolol in patients with type 2 diabetes mellitus and hypertension. A randomized controlled trial for the GEMINI Investigators. JAMA, 292:2227–2236, 2004.
Billinger, M., Seiler, C., Fleisch, M. et al. Do beta-adrenergic blocking agents increase coronary flow reserve? J. Am. Coll. Cardiol., 38:1866–1871, 2001.
Carlberg, B., Samuelsso, O., Lindholm, L. H. et al. Atenolol in hyper¬tension: Is it a wise choice? Lancet, 364:1684–89, 2004.
CAPRICORN investigators: Effect of carvedilol on outcome after myocardial infarction in patients and with left ventricular dysfunction. Lancet, 357:138, 2001.
CIBIS-II: The cardiac insufficiency bisoprolol study II. A randomized trial. Lancet, 353:9–13, 1999.
COMET: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET). A randomized controlled trial. Lancet, 362:7–13, 2003.

Страницы: 1 | 2 | 3